NHS Framework Agreement - Hepatitis C Medicines
key details
| Value | £180,000,000 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Region | North East, North West, Yorkshire and the Humber, East Midlands, West Midlands, East of England, London, South East, South West |
| Deadline | 29 Jan 2018 |
| Contract start | 1 Apr 2018 |
| Contract end | 31 Mar 2019 |
| Procedure | open |
| SME suitable | Yes |
| OCID | ocds-b5fd17-1c33d335-2d00-4da2-8f8f-7c8a518ef2bd |
Awards (4)
This procurement was awarded to 4 suppliers. Values shown are per-award; the notice total is £180,000,000.
| Supplier | Value | Date | Status |
|---|---|---|---|
| AbbVie Ltd shared | £180,000,000 | 15 Apr 2018 | active |
| Gilead Sciences Ltd shared | £180,000,000 | 15 Apr 2018 | active |
| Merck Sharp and Dohme Ltd shared | £180,000,000 | 15 Apr 2018 | active |
| Roche Products UK Ltd shared | £180,000,000 | 15 Apr 2018 | active |
description
NHS Framework Agreement for Hepatitis C medicines for Midlands & East and North of England regions and NHS Framework Agreement for Hepatitis C Medicines for London and South of England regions
Period of framework agreement:
CM/PHR/17/5560/01 - Hepatitis C medicines for Midlands & East and North of England - 1 April 2018 - 28 March 2019 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.
CM/PHR/17/5560/02 - Hepatitis C medicines for Midlands & East and North of England and Hepatitis C Medicines for London and South of England - 1 April 2018 - 28 March 2019 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months
Additional information:
Attached is the model form framework agreement. All of the awarded frameworks were made on the basis of the model form framework agreement.
Redacted award schedules have been attached for each of the awarded suppliers.
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 21 May 2018 | Award (award) | · | 2992a566-9dee-4a1e-9d7a-c8ced6fec880-217278 |
more from NHS England
- Market Engagement Event for East ofEngland prisons · £0 · 11 Sept 2026
- Finance Transformation & Enablement Project Support · £7,944,879 · 10 Sept 2026
- Provision of Public Consultation and Engagement Services for the UISPC · £155,000 · 8 Sept 2026
- Targeted Lung Health Checks National Licences · £1,900,000 · 8 Sept 2026
- Adult Screening and Personalisation Digital Delivery Services · £215,163,316 · 4 Sept 2026
- Step into the NHS - Schools Programme · £65,800 · 2 Sept 2026
- Website hosting and support for hee.nhs.uk and healthcareers.nhs.uk · £168,336 · 1 Sept 2026
- NHS Login Run and Maintain 2 · £30,000,000 · 28 Aug 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.